Skip to main content
. 2021 Jun 22;16(2):216–227. doi: 10.5009/gnl210044

Table 1.

Demographic and Clinical Characteristics of 418 Patients with Crohn’s Disease in the Songpa-Kangdong District of Seoul, Korea, in 1986–2015

Clinical characteristics Year of diagnosis
Total Cohort 1 (1986–2003) Cohort 2 (2004–2015) p-value
No. of patients 418 (100) 110 (26.3) 308 (73.7)
Male sex 318 (76.1) 83 (75.5) 235 (76.3) 0.897
Age at diagnosis, median (IQR), yr 22 (18–29) 21 (17–27) 23 (18–31) 0.089
Age at diagnosis, yr 0.072
≤16 (A1) 56 (13.4) 16 (14.6) 40 (13.0)
17–40 (A2) 324 (77.5) 90 (81.8) 234 (76.0)
>40 (A3) 38 (9.1) 4 (3.6) 34 (11.0)
Interval from symptom onset to diagnosis, median (IQR), mo 10.0 (3.2–35.0) 14.8 (5.5–37.7) 8.9 (2.6–29.8) 0.005
Current smoking at diagnosis 118 (28.2) 34 (30.9) 84 (27.3) 0.537
Family history of IBD 32 (7.7) 9 (8.2) 23 (7.5) 0.835
Disease location at diagnosis 0.525
Ileum (L1) 104 (24.9) 23 (20.9) 81 (26.3)
Colon (L2) 39 (9.3) 10 (9.1) 29 (9.4)
Ileocolon (L3) 275 (65.8) 77 (70.0) 198 (64.3)
Upper GI involvement (L4) 94 (22.5) 19 (17.3) 75 (24.4) 0.144
Disease behavior at diagnosis 0.814
Nonstricturing, nonpenetrating (B1) 339 (81.1) 91 (82.7) 248 (80.5)
Stricturing (B2) 34 (8.1) 9 (8.2) 25 (8.1)
Penetrating (B3) 45 (10.8) 10 (9.1) 35 (11.4)
Perianal fistula before or at diagnosis 181 (43.3) 49 (44.5) 132 (42.9) 0.823
Duration of follow-up, median (IQR), mo 123.7 (78.9–181.1) 223.4 (200.1–256.3) 100.8 (70.2–135.6) <0.001
Ever use of medications
Systemic corticosteroids 245 (58.6) 83 (75.5) 162 (52.6) <0.001
Thiopurines 340 (81.3) 88 (80.0) 252 (81.8) 0.776
Methotrexate 11 (2.6) 3 (2.7) 8 (2.6) 0.645
Anti-TNF agents 155 (37.1) 46 (41.8) 109 (35.4) 0.251
Vedolizumab 4 (1.0) 3 (2.7) 1 (0.3) 0.058
Ustekinumab 6 (1.4) 2 (1.8) 4 (1.3) >0.999

Data are presented as number (%) unless otherwise indicated.

IQR, interquartile range; IBD, inflammatory bowel disease; GI, gastrointestinal; TNF, tumor necrosis factor.